Mangalam Drugs And Organics Limited has informed the Exchange about Copy of Newspaper Publication
MANGALAM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Mangalam Drugs filed a copy of the newspaper publication of its audited standalone and consolidated financial results for Q4 and full year ended March 31, 2025, as required under SEBI listing rules. For FY25, total income from operations stood at Rs 31,823.02 lakhs, down from Rs 36,850.47 lakhs in FY24. Despite the revenue drop, the company turned around to a net profit of Rs 692.43 lakhs in FY25 compared to a net loss of Rs 904.89 lakhs in FY24. Q4 FY25 net profit, however, was thin at Rs 15.09 lakhs versus Rs 354.61 lakhs in Q4 FY24. Full-year EPS improved to Rs 4.37 from a loss of Rs 5.72 per share in the previous year.
The full-year return to profitability after a prior-year loss is a positive signal for shareholders, showing the company is recovering at the bottom line. However, the sharp revenue decline and weak Q4 profit suggest ongoing pressure on the topline, which may temper near-term stock sentiment.